Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

July 19, 2017

Study Completion Date

July 19, 2017

Conditions
Anemia in End-Stage Renal Disease
Interventions
DRUG

CinnaPoietin®

The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.

DRUG

Eprex®

The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.

DRUG

Nephrovit

Nephrovit tablet is daily administered to all the patients.

DRUG

Vitamin B12 Injection

Vitamin B12 is monthly injected to all the patients.

Trial Locations (8)

Unknown

Javad-al-Aemeh clinic, Kerman

SHAFA Hospital, Kerman

Haj Ebrahimi dialysis center, Shiraz

Ghiasi hospital, Tehran

Hashemi Nezhad Hospital, Tehran

Imam Hussein Hospital, Tehran

Madar dialysis center, Tehran

Milad Hospital, Tehran

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cinnagen

INDUSTRY